HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

IL-6 blockers in systemic onset juvenile idiopathic arthritis.

Abstract
IL-6 has a key role in the pathogenesis, clinical manifestations and activity of Systemic Onset Idiopathic Arthritis (sJIA). Tocilizumab (TCZ), the first humanized antihuman IL-6 receptor antibody, inhibits the activity of IL-6. In this review, we summarize the main studies performed, to date, about the use of TCZ in children affected by sJIA refractory to conventional treatment. Nowadays TCZ can be used, alone or in association with Metotrexate, in children older than 2 years. Its use in children younger than 2 years is being investigated. Further study about its use in sJIA and other type of idiopathic arthritis should be done.
AuthorsPatrizia Barone, Rossana Pignataro, Maria Teresa Garozzo, Salvatore Leonardi
JournalImmunotherapy (Immunotherapy) Vol. 8 Issue 1 Pg. 79-87 ( 2016) ISSN: 1750-7448 [Electronic] England
PMID26642378 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Interleukin-6
  • Receptors, Interleukin-6
  • tocilizumab
  • Methotrexate
Topics
  • Antibodies, Monoclonal, Humanized (immunology, therapeutic use)
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Juvenile (immunology, therapy)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Humans
  • Immunotherapy
  • Infant
  • Interleukin-6 (metabolism)
  • Methotrexate (therapeutic use)
  • Receptors, Interleukin-6 (antagonists & inhibitors, immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: